{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "MMED",
  "name": "MiniMed Group, Inc.",
  "url": "https://frontierpicks.com/dossiers/MMED/",
  "json_url": "https://frontierpicks.com/dossiers/MMED.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Carve-out re-rate extended: MMED closed $20.45 on 2026-08-21, through the prior $20.48 high, after Flex began U.S. shipment integrated with Abbott's Instinct sensor on 2026-08-17 — the last open product item. Reimbursement and integration are now printed; growth rate and split-off mechanics both resolve on 2026-09-01, when MiniMed and Medtronic report the same quarter the same morning.",
  "invalidation_trigger": "A weekly close below $18.00 surrenders the entire post-Medicare-access, post-Instinct leg built in August; secondary: Q1 FY2027 on 2026-09-01 printing organic growth under the 8.7% Q4 FY2026 pace, a cut to the ~10% organic / ~16% adjusted-EBITDA FY2027 guide, or Medtronic pivoting from a split-off to a pro-rata spin into the ~10% float.",
  "catalyst_date": "2026-09-01",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "medtech-diagnostics",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Public float is roughly 10%; every quote reflects that thin base.",
    "Medtronic's stated preferred path is a split-off (exchange of MDT shares for MMED shares), targeted complete by end of calendar 2026, with no obligation to complete it.",
    "Fiscal year ends in late April. Fiscal labels run ahead of the calendar: Q1 FY2027 is the quarter ended 2026-07-31.",
    "IPO priced 2026-03-06 at $20.00 (28M shares). A customary 180-day lock-up would land in early September 2026; S-1 terms are unverified here.",
    "Abbott is supplier and competitor simultaneously: it supplies the Instinct sensor integrated with 780G and Flex while Libre CGM competes with MiniMed's own sensors.",
    "No FY2027 EPS guidance was issued. FY2026 net loss attributable was roughly $333M; Q4 FY2026 EPS was -$0.68."
  ],
  "body_markdown": "\n> Refresh of coverage first published 2026-06-09, last updated 2026-08-15. Reference close: $20.45 on 2026-08-21.\n\n## MMED — MiniMed Group, Inc.\n\n## Current Thesis\n\nTwo things moved since the 2026-08-15 note. Price closed $20.45 on 2026-08-21 against $20.15 on 2026-08-14, clearing the $20.48 level cited as the 52-week high in that note, with a three-month price change of +72.3% and RSI(14) at 61.4. And on 2026-08-17 the product item the prior note could only flag as \"~2026-09 (est.)\" landed: MiniMed announced that the MiniMed Flex system is commercially shipping in the U.S. integrated with Abbott's Instinct continuous glucose sensor — the 15-day sensor, paired with a 300-unit reservoir and a 7-day extended infusion set, with the release citing real-world 80% Time in Range and over 90% overnight.\n\nThat was the last open pre-print item on the product leg. What is still unresolved is the number. MiniMed reports fiscal Q1 2027 — the quarter ended 2026-07-31 — on Tuesday **2026-09-01**, release ~3:45 a.m. PDT and webcast 5:45–6:30 a.m. PDT. Medtronic reports the same quarter the same morning, release 5:45 a.m. CT and webcast from 6:45 a.m. CT, and the parent's call is where separation mechanics get updated against the stated end-of-calendar-2026 completion target.\n\nThe narrative leg an investor is buying: the one vendor selling a fully integrated diabetes stack — pump, smart pen, sensor and dosing algorithm — reprices as a standalone growth franchise once Medtronic's 90.03% stake is distributed. Reimbursement (2026-07-22) and integration (2026-08-17) have now both printed. The growth rate and the exchange mechanics have not.\n\n## Bull Case\n\n- **The full-stack claim is now shipping, not promised.** Flex with Abbott's Instinct sensor entered U.S. commercial shipment on 2026-08-17. The prior note listed this as undated and warned that slippage past 2026-09-01 would be a checkable delay; it arrived two weeks early instead.\n- **Payer access preceded it.** Flex became available to Medicare and Medicare Advantage beneficiaries on 2026-07-22, following FDA clearance 2026-03-18 and U.S. commercial launch 2026-06-17.\n- **Coverage widened and marked up.** UBS initiated Buy with a $25 target on 2026-07-28; Bank of America raised to $24 from $20 on 2026-08-10. MarketBeat's forecast page as of 2026-08-23 shows a $21.62 consensus target across 16 analysts, 13 Buy / 2 Hold / 1 Sell, with a $26 high and a $16 low (Piper Sandler at Hold, $16).\n- **The revenue base is real.** Q4 FY2026, reported 2026-06-03, delivered $837M against $826.52M consensus, +15.6% reported. FY2026 revenue passed $3B for the first time at roughly $3.1B, +14.3% YoY, with management citing international demand, sensor availability and 780G uptake.\n- **Guidance survived the IPO year.** FY2027 outlook is ~10% organic revenue growth, including 1.0–1.5 points from an extra week, at a ~16% adjusted EBITDA margin.\n\n## Bear Case\n\n- Public float is ~10%; a 72.3% three-month move on that base is a small quantity of stock setting the price for a very large quantity that has not traded.\n- **Organic growth was decelerating into the run.** Q4 FY2026 organic growth was 8.7%, below the consecutive double-digit organic quarters the IPO deck was built on, and the FY2027 ~10% guide leans on 1.0–1.5 points of extra-week benefit.\n- **Losses are wide and unanchored.** Q4 FY2026 EPS was -$0.68 against a -$0.22 estimate, with $183M net loss attributable in the quarter and roughly $333M for FY2026. No FY2027 EPS guidance was given, so there is no company-supplied line to grade the bottom line against on 2026-09-01.\n- **Price has closed most of the gap to the sell side.** At $20.45 on 2026-08-21 against a $21.62 mean target as of 2026-08-23, roughly 5.7% separates the two. Further upside from here needs estimate revisions rather than target catch-up.\n- **Abbott sits on both sides.** The 2026-08-17 integration deepens dependence on a supplier whose Libre CGM franchise competes with MiniMed's own sensor line.\n\n## Setup & Price Structure\n\n- **Where the price is.** $20.45 close on 2026-08-21, above the $20.00 IPO price (priced 2026-03-06, closed 2026-03-09) and above the $20.48 prior high cited on 2026-08-15. RSI(14) at 61.4 sits below the conventional 70 threshold despite the +72.3% three-month change — momentum has been persistent rather than vertical.\n- **How recent the last leg is.** A third-party quote page reported MMED at $19.60 on 2026-08-07 against a prior close of $18.42, which places the move through $20 inside the final two-and-a-half weeks before the reference close. The August advance is thin in time, which is what makes an $18 handle a structural level rather than an arbitrary one.\n- **The narrative is maturing.** Dating it: the narrative gained its two fresh catalysts on 2026-07-22 (Medicare) and 2026-08-17 (Instinct shipping) and both are now public; the last named target action was 2026-08-10 (BofA to $24), nearly two weeks before the reference close; coverage has broadened to 16 analysts with the mean target only 5.7% above spot; and the re-rate has completed the round trip back through the March IPO price. Attention is broad and the flow is moderating. It is not saturated — 13 of 16 ratings are Buy and none of the September events have resolved — but the phase where new coverage alone carried price has passed.\n- **Crowding and positioning observables (stated as observables, not verdicts).** A ~10% float against a 90.03% parent stake. A binary print nine days past the reference close. Price at the top of its post-IPO range with the consensus mean only marginally above. A customary 180-day lock-up window measured from the 2026-03-09 IPO close would land in early September; the specific S-1 terms are not verified here. No Form 4 or secondary-offering filing appears in the material available for this refresh — the supply question in this name is the parent's block, not insider trickle.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-09-01** — MiniMed fiscal Q1 2027 results, quarter ended 2026-07-31. Release ~3:45 a.m. PDT, webcast 5:45–6:30 a.m. PDT.\n- **2026-09-01** — Medtronic fiscal Q1 2027 results, same quarter end, same morning. Release 5:45 a.m. CT, webcast from 6:45 a.m. CT.\n- **~2026-09-05 (est., unconfirmed)** — 180-day window from the 2026-03-09 IPO close, if the customary lock-up shape applies. Flagged rather than asserted; the S-1 terms were not verified for this note.\n- **~2026-09 to 2026-12 (est.)** — any exchange-offer or registration filing giving the split-off its mechanics and ratio, against Medtronic's stated end-of-calendar-2026 completion target.\n\n## What Would Change Our Mind\n\nThe structural break is the August advance itself. Price spent 2026-08-07 near $19.60 with a prior close reported at $18.42 and only cleared $20 in the final stretch before 2026-08-21; giving that band back would put the shares underneath the entire post-Medicare-access, post-Instinct leg and re-open the July range. Expressed as a gradeable condition: **a weekly close below $18.00**.\n\nThree fundamental conditions would do the same work on a slower clock. First, Q1 FY2027 organic growth printed 2026-09-01 below the 8.7% Q4 FY2026 pace, or any trim to the ~10% organic / ~16% adjusted EBITDA FY2027 guide — the standalone-growth-franchise case is the reason for the multiple. Second, Medtronic on its 2026-09-01 call pivoting from a split-off to a pro-rata spin, or pushing separation past end-of-calendar-2026, since a pro-rata distribution drops shares into a ~10% float instead of retiring MDT stock against them. Third, the 2026-09-01 date coming and going with no update on exchange mechanics at all, which would leave the second half of the narrative undated for another quarter with price already at the highs.\n\nA downgrade or target cut in the two weeks after the print, uncompensated by a new initiation, would mark the coverage cycle turning from tailwind to headwind.\n\n## Correlation Notes\n\n- **MDT (Medtronic)** — holds 90.03%, reports the same morning, and controls the mechanics and timing of the distribution. Split-off commentary on the MDT call is a direct input to the MMED float, and the exchange ratio makes the two prices mechanically linked once terms exist.\n- **ABT (Abbott)** — supplier and competitor at once after 2026-08-17. Instinct supply, pricing or clinical news now transmits into MMED unit economics; Libre share gains cut the other way against MiniMed's own sensor line.\n- **DXCM, PODD, TNDM** — automated-insulin-delivery group beta. The 2026-07-16/17 reclaim off $15.40 had a borrowed sector trigger with no MiniMed-specific news, so the name has already demonstrated it moves on category flow.\n- **GLP-1 complex (LLY, NVO)** — headlines on incretin adoption feed the category question of whether insulin-pump patient starts compress. Any of PODD, DXCM or TNDM naming GLP-1 as a new-patient headwind at their next print would read across.",
  "first_seen": "2026-06-09",
  "last_analyzed": "2026-08-23T14:16:52+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}